| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Healthcare Triangle, Inc. Common Stock$1.64
+0.01 (+0.61%)
Market Cap
2.77 M
EPS
-
P/E Ratio
-
Value Trade
102.94 K
SEC Financials
Q1 2026Dilution Risk
Revenue
9.86 M
R&D Expenses
85.00 K
Operating CF
-6.86 M
Total Assets
80.16 M
Total Liabilities
27.46 M
Equity
52.70 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
4.32 M
Monthly Burn
2.29 M
Runway
0 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
24.61 K
52 Week Range
2.24 - 7,469.93
% held by Insiders
6.01 %
% held by Institutions
5 %
Enterprise Value
10.09 M
Total Shares
2.03 M
Short %
7.38 %
Float Shares
2.03 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HCTI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HCTI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-HCTI
Jul 29, 2026▲ +0.6%today
Healthcare Triangle Completes Share Issuances Relating to Legacy M&A Transactions, Strengthening Compliance With Nasdaq's New $5 Million Market Value Listing Standard
Healthcare Triangle, Inc. has completed the issuance of over 12.5 million shares, enhancing its compliance with Nasdaq's new $5 million market value requirement. This increase follows two shareholder-approved transactions, including the acquisition of Teyame AI LLC. The company's market value now stands at approximately $23.87 million, bolstering its position for continued listing on Nasdaq.
Read more →-HCTI
Jul 27, 2026▲ +0.6%today
Healthcare Triangle Creates "Purpose Health" to Monetize AI Demand and Accelerate Shareholder Returns
Healthcare Triangle, Inc. has appointed Sumit Ganguli as the Chairman and CEO of its subsidiary, Purpose Health, to enhance its AI-driven healthcare services. The company aims to capitalize on high-margin recurring revenue models while expanding its market presence in the U.S. and internationally. Ganguli's extensive experience in scaling healthcare technology businesses is expected to accelerate Purpose Health's growth and innovation.
Read more →-HCTI
Jun 12, 2026▼ -5.9%on this news
WallachBeth Capital Announces Closing of Healthcare Triangle, Inc. Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of Approximately $3.6 Million
WallachBeth Capital has successfully closed a private placement offering for Healthcare Triangle, Inc., raising approximately $3.6 million through senior convertible promissory notes. The notes, which mature in December 2026, are convertible at a price based on the company's stock performance. The proceeds will be allocated for debt repayment, potential acquisitions, and working capital.
Read more →-HCTI
Jun 12, 2026▼ -10.1%on this newsshared move
Healthcare Triangle, Inc. Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of Approximately $3.6 Million
Healthcare Triangle, Inc. has announced the closing of a private placement offering of senior convertible promissory notes, raising approximately $3.6 million. The notes, maturing on December 12, 2026, are convertible at the holder's option after six months. Proceeds will be utilized for debt repayment, potential acquisitions, and general working capital.
Read more →-HCTI
May 14, 2026Healthcare Triangle Reports 627% Increase in Gross Profit and 166% Increase in Revenue for Q1 2026
Healthcare Triangle, Inc. reported a remarkable 166% increase in revenue and a 627% rise in gross profit for Q1 2026, driven primarily by its recent acquisitions of Teyame 360 S.L. and Datono Mediacion S.L. These acquisitions contributed significantly to the company's financial performance, establishing a new Customer Engagement Services segment. Management anticipates continued improvements in gross margins as integration progresses.
Read more →-HCTI
Apr 23, 2026▼ -9.3%on this news
Healthcare Triangle, Inc. Launches AI-Driven Digital Self-Care Therapy Platform "ZoraNex" to address the $450B Global Mental Health Market
Healthcare Triangle, Inc. has launched ZoraNex, an AI-driven digital self-care therapy platform aimed at addressing the global mental health crisis. This platform combines Western and Eastern therapeutic practices to provide accessible mental health support for individuals experiencing mild to moderate issues. ZoraNex will be available on major app stores by the end of Q2 2026, targeting Southeast Asia as a key growth region.
Read more →-HCTI
Mar 11, 2026▲ +12.5%on this news
Healthcare Triangle, Inc. Announces Approval of $2 Million Share Repurchase Plan
Healthcare Triangle, Inc. has announced the approval of a $2 million share repurchase plan by its Board of Directors. The plan allows the company to buy back its outstanding common stock through various methods and is effective immediately. This move is aimed at enhancing shareholder value and demonstrates the Board's confidence in the company's long-term business strategy. Additionally, it provides the necessary flexibility to manage shares based on market conditions and corporate liquidity requirements.
Read more →-HCTI
Feb 26, 2026▼ -13.6%on this news· ran to -50% by day 3
Healthcare Triangle Announces Approximately $3.959 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
Healthcare Triangle, Inc. has announced a registered direct offering of 681,553 shares of common stock at a price of $5.81 per share. The offering is expected to generate gross proceeds of approximately $3.959 million and is set to close on February 27, 2026, pending customary closing conditions. This financing will enhance the company's position in the digital transformation space within healthcare and life sciences.
Read more →-HCTI
Feb 6, 2026▼ -28.8%on this news· ran to -39% by day 3
Healthcare Triangle, Inc. Announces 1-for-60 Reverse Stock Split as Part of Nasdaq Compliance Plan
Healthcare Triangle, Inc. announced a 1-for-60 reverse stock split effective February 10, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. This measure, approved by shareholders, is expected to increase the stock price and align the company with exchange regulations. The split will reduce the number of outstanding shares and is part of a broader corporate strategy to enhance market performance.
Read more →-HCTI
Jan 22, 2026▼ -7.7%on this news
Healthcare Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Eur
Healthcare Triangle, Inc. (HCTI) has signed a definitive agreement to acquire Teyame AI LLC, which is anticipated to generate $38 million in additional next twelve months (NTM) revenue and $5 million in NTM EBITDA. The acquisition, part of a strategic move to enhance HCTI's healthcare and life sciences digital solutions, will also expand its SaaS offerings in Europe and Latin America. The deal, valued at up to $50 million, includes cash, stock, and earnouts, with a closing date expected on January 29, 2026. The integration of Teyame’s AI-powered customer experience platforms is projected to foster an intelligent ecosystem for patient engagement.
Read more →-HCTI
Dec 10, 2025▲ +11.9%on this news
Healthcare Triangle, Inc. Signs Advance Agreement for the Acquisition of Next-Generation AI Customer Engagement Business, on track to generate $34M in Revenue for FY 2025
Healthcare Triangle, Inc. has signed an Advance Agreement to acquire Teyame AI LLC, an AI customer engagement business. This strategic acquisition is projected to generate approximately $34 million in revenue for FY 2025 and elevate HCTI's position in the AI-powered customer engagement sector. The total consideration for the deal is anticipated to be around $50 million, contingent upon customary closing conditions and shareholder approval. The integration aims to enhance patient engagement and create a next-generation ecosystem influential in the healthcare industry.
Read more →-HCTI
Oct 2, 2025▼ -5.5%on this news
Update - Healthcare Triangle Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $1.63 Million
Healthcare Triangle, Inc. announced it has entered into warrant exercise agreements with accredited and institutional investors for $1.63 million. This involves the immediate exercise of existing warrants to purchase 812,775 shares of common stock. In return, investors will receive new unregistered warrants with an exercise price of $3.00 per share. The offering is set to close on or about October 2, 2025, pending customary closing conditions.
Read more →-HCTI
Sep 15, 2025Healthcare Triangle, Inc. (NASDAQ: HCTI) Transforming Healthcare Through EHR, Cloud, and A.I. Driving Growth, Building Value 2 Forward - Looking Statements This presentation contains forward - looking statements within t
Healthcare Triangle, Inc. (HCTI) outlined its growth strategy focusing on EHR, Cloud, and AI technologies during a recent presentation. The company aims for approximately $20 million in revenue by 2025, supported by strong gross margins and a stable recurring base through multi-year contracts. They are expanding globally and leveraging strategic partnerships with major technology firms. However, HCTI acknowledges risks such as market demand fluctuations and regulatory developments which may influence its growth trajectory.
Read more →-HCTI
Jul 30, 2025Healthcare Triangle, Inc. Announces 1-for-249 Reverse Stock Split as Part of Nasdaq Compliance Plan
Healthcare Triangle, Inc. announced a 1-for-249 reverse stock split effective August 1, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00. This move was approved by stockholders and aims to increase the share price and improve market positioning. Following the split, the number of shares outstanding will reduce significantly, which is a strategic effort to enhance investor confidence. Information regarding share ownership will be sent to stockholders post-split.
Read more →-HCTI
Jul 7, 2025Healthcare Triangle, Inc. Announces Nasdaq Hearings Panel's Grant of the Company's Request for Continued Listing of its Securities. Pleasanton, California
Healthcare Triangle, Inc. announced that the Nasdaq Hearings Panel granted its request to continue listing its securities on the Nasdaq. This decision follows a review of compliance with Nasdaq’s shareholder equity rule, allowing the company to resolve prior deficiencies. The company expressed gratitude for the decision and communicated its commitment to advancing its strategic growth plan, while a Discretionary Panel Monitor will oversee compliance for the next year.
Read more →-HCTI
Jun 16, 2025Healthcare Triangle Completes Strategic Acquisition of Niyama Healthcare and Ezovion Solutions Pleasanton, California
Healthcare Triangle, Inc. announced the completion of its acquisition of Niyama Healthcare and Ezovion Solutions, which enhances its presence in the digital healthcare sector. The acquisition supports HCTI's mission to advance healthcare through integrated platforms and technologies. This strategic move is expected to add both financial and operational benefits, particularly in mental health and hospital information systems. Niyama will assist with operational continuity during the transition period until August 2025.
Read more →-HCTI
Apr 11, 2025Healthcare Triangle announces the appointment of Chief Financial Officer and Director on the Board. PLEASANTON, Calif., April 11 th , 2025 (NEWMEDIAWIRE) -- Healthcare Triangle, Inc (Nasdaq: HCTI) ("HCTI" or the "Company
Healthcare Triangle, Inc. has announced two significant executive appointments to enhance its leadership team. David Ayanoglou is appointed as Chief Financial Officer, bringing over 22 years of experience in corporate finance and M&A, while Sujatha Ramesh, currently the COO, has been appointed as a Director on the Board. Both appointments are intended to support the company's strategic growth and operational excellence amid its ongoing global expansion and transformation initiatives.
Read more →-HCTI
Mar 18, 2025Healthcare Triangle announces the appointment of Chief Operating Officer
Healthcare Triangle, Inc. has appointed Sujatha Ramesh as its new Chief Operating Officer. With over 25 years of experience, she aims to lead the company in its next phase of growth by enhancing operational efficiency and delivering innovative technology solutions. Previously, Ramesh held senior roles at major corporations like Citigroup and is recognized in the industry for her expertise in strategic transformation and governance frameworks. Her appointment is expected to significantly contribute to Healthcare Triangle's ongoing digital transformation efforts in the healthcare sector.
Read more →-HCTI
Feb 27, 2025Healthcare Triangle, Inc Announces $15.2 Million PIPE Offering. Healthcare Triangle, Inc (NASDAQ: HCTI) ("HCTI" or the "Company")
Healthcare Triangle, Inc. announced a PIPE offering expected to raise approximately $15.2 million. This offering includes shares and warrants that can enhance the company’s liquidity and financial flexibility. The funds are intended to support HCTI's ongoing initiatives in digital transformation for healthcare and life sciences. Co-placement agents for the offering include RBW Capital, LLC and Spartan Capital Securities, LLC, with details to be filed with the SEC.
Read more →-HCTI
Mar 12, 2024Healthcare Triangle, Inc. Appoints Anand Kumar as Interim
Healthcare Triangle, Inc. has appointed Anand Kumar as interim Chief Executive Officer, in addition to his role as Chief Revenue Officer. Kumar brings over two decades of experience in the healthcare technology sector and is expected to drive innovation and growth during this transitional phase. The company emphasizes its commitment to utilizing digital transformation and AI to enhance its services. Kumar's leadership is seen as crucial for navigating the complexities of the regulated healthcare environment.
Read more →-HCTI
Jan 2, 2024Healthcare Triangle, Inc. Completes $2.0 Million Private Placement Debt Offering
Healthcare Triangle, Inc. announced the completion of a $2 million private placement debt offering with an institutional investor. The offering includes senior secured convertible promissory notes and associated warrants, providing HCTI with net proceeds of approximately $1.5 million. This capital is intended to help the company meet critical needs in the healthcare sector and enhance its position as a leading healthcare IT provider in the U.S. A registration statement for the securities will be filed shortly.
Read more →-HCTI
May 25, 2023Healthcare Triangle, Inc. Announces 1-for-10 Reverse Stock Split as Part of Nasdaq Compliance Plan
Healthcare Triangle, Inc. has announced a 1-for-10 reverse stock split of its common stock as part of a compliance strategy with the Nasdaq's minimum bid price requirement of $1.00. The reverse stock split will take effect on May 26, 2023, reducing the number of shares outstanding from approximately 42.8 million to about 4.3 million. This financial move aims to increase the price per share and stabilize the company's stock, while shareholders received approval for the split at the company's annual meeting.
Read more →-HCTI
Dec 29, 2022By Electronic Delivery to: rt@healthcaretriangle.com ; rcarmel@cmfllp.com
Electronic Delivery to: rt@healthcaretriangle.com; rcarmel@cmfllp.com Thyagarajan Ramachandran Stoneridge Dr., Suite 220 you are aware, due to the resignations of Mr. Jeffrey S. Mathiesen, Mr. John Leo and Ms. April Bjornstad from the Company's board, audit committee and comp
Read more →-HCTI
Jul 11, 2022Healthcare Triangle Announces $6.5 Million Private Placement
Triangle Announces $6.5 Million Private Placement Calif., July 11, 2022 (GLOBE NEWSWIRE) - Healthcare Triangle Inc., (Nasdaq: HCTI) ("HCTI" or the "Company"), a leading provider of cloud and data transformation solutions for healthcare and life sciences, today announced that i
Read more →-HCTI
Dec 13, 2021Healthcare Triangle (HCTI) Acquires DevCool, an Electronic Health Record (EHR) Focused Healthcare IT and Managed Services Company Acquisition Expected to Add Approximately $20 Million in Revenues
Triangle (HCTI) Acquires DevCool, an Electronic Health Record (EHR) Focused Healthcare IT and Managed Services Company Expected to Add Approximately $20 Million in Revenues Calif., December 13, 2021- Healthcare Triangle, Inc. (HCTI), a leading provider of Healthcare and Life Sc
Read more →-HCTI
Oct 12, 2021Healthcare Triangle, Inc. Announces Pricing of $13.0 Million Initial Public Offering
Triangle, Inc. Announces Pricing of $13.0 Million Initial Public Offering 12, 2021 19:44 ET | Source: Healthcare Triangle, Inc. Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. ("HTI" or the "Company"), a leader in the public cloud for Hospitals, Health Syst
Read more →Competitive Position
How HCTI ranks across every disease it competes inCompetitive Position is a premium feature
See how HCTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial